PDX modeling receives significant support from governmental agencies worldwide. In 2017, the US National Cancer Institute (NCI) established the PDXNet to facilitate collaboration among researchers and advance the vision of cancer precision medicine through the application of PDX models.
In combination with several molecular profiling techniques, the “Mouse Avatar” and Co-Clinical Trial concepts have the potential to revolutionize the drug development and health care process.1-2
References: 1 Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov. 2014 Sep;4(9):998-1013. 2 Malaney, P., Nicosia, S. V., & Davé, V. (2014). One Mouse, One Patient Paradigm: New Avatars of Personalized Cancer Therapy. Cancer Letters, 344(1), 1–12.